Medical specialists from Australia tagged as investigators in clinical trials studying Hyperlipoproteinemia Type I

Total 5 results

Anne Reutens, MD
Seen in:
- Victoria, Melbourne, Baker Heart and Diabetes Institute
Trials:
- NCT05089084 (Principal Investigator)
Conditions:
- Familial Chylomicronemia
David Sullivan, MD
Seen in:
- New South Wales, Camperdown, Royal Prince Alfred Hospital
Trials:
- NCT05089084 (Principal Investigator)
Conditions:
- Familial Chylomicronemia
Elif Ekinci, MD
Seen in:
- Melbourne, Austin Health
Trials:
- NCT05089084 (Principal Investigator)
Conditions:
- Familial Chylomicronemia
Gerald Watts, MD
Seen in:
- Nedlands, Linear Clinical Research Ltd
Trials:
- NCT05089084 (Principal Investigator)
Conditions:
- Familial Chylomicronemia
Sarah Glastras, MD
Seen in:
- New South Wales, St. Leonards, Royal North Shore Hospital
Trials:
- NCT05089084 (Principal Investigator)
Conditions:
- Familial Chylomicronemia

Clinical Trials on Hyperlipoproteinemia Type I

S.LAB (SOLOWAYS)
Center of New Medical Technologies; Triangel Scientific

Completed

Evaluating the Impact of Omega-3 Fatty Acid Supplementation (Soloways™) on Lipid Profiles in Adults With PPARG Polymorphisms (SOLIPARG)

LDL Hyperlipoproteinemia | Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia | Triglyceride Storage Type I or II Disease

Russian Federation
UniQure Biopharma B.V.

Completed

Glybera Registry, Lipoprotein Lipase Deficient (LPLD) Patients (GENIALL)

Lipoprotein Lipase Deficiency | Familial Hyperlipoproteinemia Type 1 | Familial Hyperchylomicronemia

Germany
University of Texas Southwestern Medical Center

Completed

Orlistat for the Treatment of Type I Hyperlipoproteinemia (T1HLP)

Hypertriglyceridemia | Hyperlipoproteinemia Type I

United States
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.

Completed

The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome

Familial Chylomicronemia Syndrome | Lipoprotein Lipase Deficiency | Hyperlipoproteinemia Type 1

United States, Canada, Germany, Israel, Italy, South Africa, Spain, United Kingdom, Brazil, France, Netherlands
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.

Completed

Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS)

Familial Chylomicronemia Syndrome | Lipoprotein Lipase Deficiency | Hyperlipoproteinemia Type 1

Canada
Amsterdam Molecular Therapeutics
ICON plc

Terminated

Duration of Effect of Alipogene Tiparvovec Treatment, Which Was Administered in Other Studies

Hyperlipoproteinemia Type I

Canada
AstraZeneca

Completed

Effect of Rosuvastatin on Triglyceride Levels in Mexican Hypertriglyceridemic Patients

Hypertriglyceridemia | Hyperlipidemia | Hyperlipoproteinemia Type V | Hyperlipoproteinemia Type IV | Hyperlipoproteinemia Type IIb

Mexico
Catabasis Pharmaceuticals

Completed

Pilot Study To Assess CAT-2003 in Patients With Chylomicronemia

Hypertriglyceridemia | Hyperlipoproteinemia Type I | Lipoprotein Lipase Deficiency, Familial | Chylomicronemia, Familial

Canada
Novartis Pharmaceuticals

Terminated

Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome.

Familial Chylomicronemia Syndrome (FCS) (HLP Type I)

South Africa, Germany, United Kingdom, France, United States, Canada, Netherlands
CENTOGENE GmbH Rostock

Withdrawn

Biomarker for Homozygous Familial Hypercholesterolemia (BioHoFH) (BioHoFH)

Lipoprotein Lipase Deficiency | Inborn Error of Lipid Metabolism | Corneal Arcus

Germany, India, Sri Lanka

Medical specialists from Australia tagged as investigators in clinical trials studying Hyperlipoproteinemia Type I

Clinical Trials on Hyperlipoproteinemia Type I

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations